natgillin/translations-raw huggingface dataset:
It is used as a consolidation therapy to improve the reduction in the number of lymphoma cells (remission) achieved with the initial chemotherapy regimen. 
Uporablja se kot konsolidacijska terapija za izboljšanje zmanjšanja števila celic limfoma (remisija), ki se doseže z začetnim režimom kemoterapije.
• Mucocutaneous reactions, including Stevens-Johnson Syndrome 
• mukokutane reakcije, vključno s Stevens-Johnsonovim sindromom
The estimated radiation-absorbed doses to normal organs were substantially below recognised upper safety limits. 
Ocenjene absorbirane doze sevanja, ki jih prejmejo normalni organi, so bile precej pod dovoljeno zgornjo varnostno mejo.
Pregnancy must be excluded before the start of treatment in women. 
Pred začetkom zdravljenja pri ženskah je treba izključiti nosečnost.
Name and address of the manufacturer of the biological active substance Biogen IDEC, Inc. 
Ime in naslov izdelovalca biološke učinkovine Biogen IDEC, Inc.
Median TTP (Months) [Range 
Mediana TTP (meseci) [razpon
1.67 to 3.34 GBq/ml 
1,67 do 3,34 GBq/ml
Studies on reproductive and developmental toxicity have not been performed. 
Študij reproduktivne in razvojne toksičnosti niso izvedli.
Total other Beta impurities (non-strontium-90) 
Skupne druge nečistote beta (ne-stroncij-90)
Mix completely by coating the entire inner surface of the reaction vial. 
Temeljito premešajte, tako da bo prekrita celotna notranja površina reakcijske viale.
• infections of the lung (pneumonia): breathing difficulties 
• okužbe pljuč (pljučnice): težave z dihanjem
Therefore, for one week after the Zevalin infusion you must wash your hands thoroughly each time after urinating. 
Zato si morate en teden po infuziji zdravila Zevalin po vsakem uriniranju skrbno umivati roke.
If any signs or symptoms of extravasation have occurred, the infusion must be immediately terminated and restarted in another vein. 
Če se pojavi kakršenkoli znak ali simptom ekstravazacije, je treba infundiranje takoj ustaviti in ga ponovno začeti v drugi veni.
net CPM bottom half x 100 net CPM top half + net CPM bottom half 
neto CPM spodnja polovica x 100 neto CPM zgornja polovica + neto CPM spodnja polovica
Zevalin will only be used in special controlled areas. 
Zdravilo Zevalin se sme uporabljati samo v posebnih nadzorovanih prostorih.
The safety and efficacy of the Zevalin therapeutic regimen were evaluated in two multi-center trials enrolling a total of 197 subjects. 
Varnost in učinkovitost zdravljenja z zdravilom Zevalin so ocenjevali v dveh multicentričnih študijah, v kateri je bilo vključenih skupno 197 oseb.
The final formulation after radiolabelling contains 2.08 mg [ 
Končna formulacija po označitvi z radioizotopom vsebuje 2,08 mg [
This medicine is a radiopharmaceutical product for therapy only. 
To zdravilo je radiofarmacevtski izdelek, namenjen samo za zdravljenje.
The prepared solution must be given as a slow intravenous infusion over 10 minutes. 
Pripravljeno raztopino je treba dati v obliki počasne intravenske infuzije, ki teče 10 minut.
Repeated use: Data on the re-treatment of patients with Zevalin are not available. 
Ponovna uporaba: Podatki o ponovnem zdravljenju bolnikov z zdravilom Zevalin niso na voljo.
Patients should be advised that fertility may be affected and that male patients may wish to consider semen cryopreservation. 
Bolnike je treba poučiti, da zdravilo lahko vpliva na plodnost in da bodo moški bolniki morda želeli svoja semenčeca shraniti z globokim zamrzovanjem.
The side effects marked with two asterisks (**) were observed additionally under consolidation therapy. 
Neželene učinke, označene z dvema zvezdicama (**), so dodatno opazili v konsolidacijski terapiji.
For storage conditions of the radiolabelled product, see section 6.3. 
Za pogoje shranjevanja radioaktivnega zdravila glejte poglavje 6.3.
Yttrium-90 decays by the emission of high-energy beta particles, with a physical half-life of 64.1 hours (2.67 days). 
Itrij-90 razpada z oddajanjem visokoenergijskih delcev beta, njegov fizikalni razpolovni čas pa je 64,1 h (2,67 dneva).
If you have been treated with other proteins (especially mouse-derived) before Zevalin treatment, you may be more likely to have an allergic reaction. 
Če ste bili zdravljeni z drugimi beljakovinami (zlasti pridobljenimi iz miši) pred zdravljenjem z zdravilom Zevalin, so pri vas alergijske reakcije bolj verjetne.
Women must not breast-feed during treatment and for 12 months following the treatment. 
Ženske ne smejo dojiti med zdravljenjem in še 12 mesecev po zdravljenju.
Pharmacotherapeutic group: Various therapeutic radiopharmaceuticals, ATC code: V10XX02 
Farmakoterapevtska skupina: Razni radioterapevtiki, oznaka ATC: V10XX02
In the following cases, Zevalin use is not recommended since its safety and efficacy have not been established: 
V naslednjih primerih se uporaba zdravila Zevalin ne priporoča, saj varnosti in učinkovitosti niso ugotavljali:
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN ZEVALIN 
KAJ MORATE VEDETI, PREDEN VAM BODO DALI ZDRAVILO ZEVALIN
Zevalin is not used directly, but must be prepared by your healthcare professional first. 
Zdravilo Zevalin se ne uporablja neposredno, temveč ga najprej pripravi zdravstveni delavec.
The maximum dose must not exceed 1200 MBq (‘megabecquerel', a unit to measure radioactivity). 
Največji odmerek ne sme preseči 1200 MBq ("megabekerelov", merske enote za radioaktivnost).
It is not shed from the cell surface and does not internalise on antibody binding. 
Ne loči se s celične površine in se po vezavi protitelesa ne internalizira.
(monotherapy) and <150,000/mm 
(monoterapija) in < 150.000/mm
Secondary efficacy endpoints included time to disease progression (TTP) and duration of response (DR). 
Sekundarna kriterija učinkovitosti sta bila čas do napredovanja bolezni (TTP) in trajanje odgovora (DR-duration of response).
Reporting suspected adverse reactions afterauthorisation of the medicinal product is important. 
Poročanje o domnevnih neželenih učinkih zdravila po izdaji dovoljenja za promet je pomembno.
- On day 1 you will be given one rituximab infusion - On day 7, 8, or 9 you will be given one rituximab infusion, followed by one Zevalin infusion shortly afterwards (within 4 hours). 
- 1. dan boste prejeli eno infuzijo rituksimaba - 7., 8. ali 9 dan boste prejeli eno infuzijo rituksimaba, ki ji bo kmalu zatem sledila ena infuzija zdravila Zevalin (v roku 4 ur).
The amount of radiation that your body will be exposed to due to Zevalin is smaller than with radiotherapy. 
Količina sevanja, ki mu bo izpostavljeno vaše telo zaradi zdravila Zevalin, je manjša kot bi bila tista pri radioterapiji.
If the average radiochemical purity is less than 95%, the preparation must not be administered. 
Če je povprečna radiokemična čistost manj kot 95 %, se pripravka ne sme dati.
Although it is not known whether ibritumomab tiuxetan is excreted in human milk, maternal IgGs are known to be excreted in human milk. 
Čeprav ni znano ali se ibritumomab tiuksetan pri ljudeh izloča v materino mleko, je znano, da se IgG matere izloča v materino mleko.
91192 Gif-sur-Yvette Cedex France 
91192 Gif-sur-Yvette Cedex Francija
Zevalin may be infused directly by stopping the flow from an infusion bag and administering it directly into the line. 
Zdravilo Zevalin se lahko infundira neposredno z ustavitvijo toka iz infuzijske vrečke in aplikacijo neposredno v linijo.
After the 5-minute incubation period, withdraw from the reaction vial the same volume of air as the formulation buffer to be added in order to normalise pressure and immediately thereafter gently add the formulation buffer down the side of the reaction vial to terminate incubation. 
Po 5-minutni inkubaciji izvlecite iz reakcijske viale enako količino zraka kot je pufer za pripravo formulacije, ki ga boste dodali za normalizacijo pritiska in takoj nato previdno dodajte pufer za pripravo formulacije v reakcijsko vialo in s tem končajte inkubacijo.
Calculate the average Radiochemical Purity (RCP) as follows: 
5) Izračunajte povprečno radiokemijsko čistoto (RCP - radiochemical purity), kot sledi:
• Additional testing that might be required for suitability assessment: Process-specific impurities: 
• Pri ocenjevanju primernosti bo morda treba opraviti naslednje dodatne teste: Za postopek značilne nečistote:
If you are given Zevalin less than 4 months after chemotherapy containing the active substance fludarabine, you may have a higher risk of having a reduced number of blood cells. 
Če dobivate zdravilo Zevalin manj kot 4 mesece po kemoterapiji, ki je vključevala zdravilno učinkovino fludarabin, je morda pri vas tveganje zmanjšanega števila krvnih celic večje.
If available, autologous stem cell support must be administered to manage haematological toxicity. 
Če so na razpolago avtologne matične celice, jih je treba uporabiti kot podporo pri obvladovanju hematološke toksičnosti.
The primary efficacy endpoint of the study was to determine the ORR using the IWRC (see Table 2). 
Primarni kriterij učinkovitosti v študiji je bil določitev ORR po kriterijih IWRC (glejte preglednico 2).
During the first 13 weeks after treatment with Zevalin, patients very commonly developed infections. 
V prvih 13 tednih po zdravljenju z zdravilom Zevalin se je pri bolnikih pogosto pojavila okužba.
However, after Yttrium-90 is added, adequate shielding of the final preparation must be maintained. 
Po dodatku itrija-90 pa je obvezna ustrezna zaščita končnega pripravka.
Metal impurities Total metals* 
Kovinske nečistote Skupne kovine*
Based upon dosimetry studies with [ 
Na podlagi dozimetričnih študij z [
Radiation protection precaution in accordance with local regulations must be taken, since administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spills of urine, vomiting, etc.. 
Potrebno je izvesti ukrepe za zaščito pred sevanjem, saj pomeni dajanje radiofarmakov tveganje za druge ljudi zaradi zunanjega sevanja ali kontaminacijo zaradi razlitega urina, bruhanja, itd.
Blood samples, used to calculate residence times for red marrow, were drawn up to eight time-points. 
Krvne vzorce za izračun rezidenčnih časov v rdečem kostnem mozgu so jemali v ustreznih časovnih presledkih do 8-krat.
If at any time in the preparation of this product the integrity of the containers is compromised it should not be used. 
Če se kadarkoli med pripravljanjem tega zdravila poškoduje kak vsebnik, zdravila ne smete uporabiti.
 0.74 MBq strontium-90 / 37 GBq yttrium-90 
 0,74 MBq stroncij-90/ 37 GBq itrij-90
Your doctor will immediately stop the infusion and restart it using another vein. 
Vaš zdravnik bo takoj ustavil infuzijo in jo prestavil na drugo žilo
Special caution is required with respect to bone marrow depletion. 
Posebna previdnost je potrebna glede na zmanjšan kostni mozeg.
Your doctor will perform tests to exclude pregnancy before you start the treatment. 
Vaš zdravnik bo pred začetkom zdravljenja opravil teste za izključitev nosečnosti.
The Package Leaflet should also be amended accordingly. 
Ustrezno je treba spremeniti tudi navodilo za uporabo.
The conjugated antibody has an apparent affinity constant for the CD20 antigen of approximately 17 nM. 
Konjugirano protitelo ima očitno afinitetno konstanto za antigen CD20, ki znaša približno 17 nM.
Zevalin is indicated in adults. 
Zdravilo Zevalin je indicirano pri odraslih.
Infections were very commonly observed. 
Okužbe so opazili pogosto.
Must be administered by authorised personnel only. 
Zdravilo sme aplicirati le pooblaščeno osebje.
WHAT ZEVALIN IS AND WHAT IT IS USED FOR 
KAJ JE ZDRAVILO ZEVALIN IN ZA KAJ GA UPORABLJAMO
The secondary endpoints, duration of response and time to progression, were not significantly different between the two treatment arms. 
Sekundarna kriterija učinkovitosti, trajanje odgovora in čas do napredovanja se v obeh krakih študije nista značilno razlikovala.
Its receipt, preparation, use, transfer, storage, and disposal are subject to the regulations and/or appropriate authorisation/licences of the local competent official organisations. 
Za prejem, pripravo, uporabo, prenos, shranjevanje in odstranjevanje veljajo predpisi in/ali ustrezna dovoljenja/licence lokalnih pristojnih uradnih organov.
Zevalin attaches to a protein (CD20) on the surface of certain white blood cells (B-cells) and kills them by irradiation. 
Zdravilo Zevalin se veže na beljakovino (DC20) na površini nekaterih belih krvnih celic (celice B) in jih uniči s sevanjem.
Zevalin therapeutic regimen N = 54 
Zevalin terapevtska shema n = 54
Zevalin therapeutic regimen N = 73 
Zevalin terapevtska shema n = 73
Studies on the mutagenic and carcinogenic potential of Zevalin have not been performed. 
Študije mutagenega in tumorogenega potenciala zdravila Zevalin niso bile izvedene.
The radiation dose to the ovaries has not been established. 
Odmerka sevanja za jajčnike niso ugotavljali.
Count each vial in a beta counter or in an appropriate counter for one minute (CPM), record net counts, corrected for background. 
Postavite vsako od vial za eno minuto v beta števec ali drug ustrezen števec (CPM), zabeležite dobljena števila s korekcijo za ozadje.
Please tell your doctor that you were given Zevalin if you are due for vaccination after using it. 
Povejte svojemu zdravniku, da ste prejemali zdravilo Zevalin, če boste po njegovi uporabi cepljeni.
For instructions on extemporary preparation of the medicinal product before administration,see section 12. 
Za navodila za pripravo zdravila tik pred uporabo glejte poglavje 12.
The infusion must not be administered as an intravenous bolus. 
Infuzije se ne sme dati v obliki intravenskega bolusa.
Name and address of the manufacturer responsible for batch release CIS bio international 
Ime in naslov izdelovalca, odgovornega za sproščanje serij CIS bio international
The maximum dose must not exceed 1200 MBq. 
Največji odmerek ne sme preseči 1200 MBq.
This may include discontinuation of Zevalin therapy and treatment with growth factors or your own stem cells. 
To lahko vključuje prekinitev zdravljenja z zdravilom Zevalin in zdravljenje z rastnimi faktorji ali lastnimi matičnimi celicami.
Due to the potential risk of developing viral infections it is not recommended to administer live viral vaccines to patients who have recently received Zevalin (see section 4.5). 
Zaradi možnega tveganja za razvoj virusne okužbe se ne priporoča uporaba živih virusnih cepiv pri bolnikih, ki so pred kratkim prejeli zdravilo Zevalin (glejte poglavje 4.5).
Therefore, complete blood cell and platelet counts must be monitored following Zevalin treatment weekly until levels recover or as clinically indicated. 
Zato je treba po zdravljenju z zdravilom Zevalin tedensko nadzirati skupno število krvnih celic in trombocitov, dokler se ravni ne povrnejo ali kakor je klinično indicirano.
Adverse reactions listed below are classified according to frequency and System Organ Class (MedDRA). 
Neželeni učinki so opredeljeni spodaj po pogostnosti in glede na organske sisteme (MedDRA).
After treatment your doctor will perform regular blood tests to check your platelet and white cell counts. 
Po zdravljenju bo vaš zdravnik v rednih časovnih intervalih opravljal krvne preiskave za spremljanje števila trombocitov in belih krvnih celic.
You may, therefore, need to be tested for special antibodies. 
Zato bodo morali pri vas opraviti preiskave za določena protitelesa.
The linker chelate tiuxetan forms a stable complex with the radioisotopes yttrium-90 and indium-111 and only negligible degradation due to radiolysis is expected. 
Vezni kelat tiuksetan tvori stabilen kompleks z radioizotopoma itrijem-90 in indijem-111, pričakovana degradacija zaradi radiolize pa je zanemarljiva.
Please see the package leaflet for further information. 
Glejte navodilo za uporabo za več informacij.
Caution: Patient dose not to exceed 1200 MBq. 
Opozorilo: Odmerek za bolnika ne sme presegati 1200 MBq.
Median time to blood platelet and granulocyte nadirs were around 60 days after start of treatment. 
Mediani čas do najnižje točke trombocitov in granulocitov je bil približno 60 dni po začetku zdravljenja.
The adverse drug reactions identified only during post-marketing surveillance, and for which a frequency could not be estimated, are listed under “not known“. 
Neželeni učinki iz obdobja trženja, za katere pogostnosti ni bilo možno oceniti, so navedeni pod „neznana“.
Treatment consists of discontinuation of Zevalin and supportive therapy, which may include growth factors. 
Zdravljenje temelji na prekinitvi aplikacij zdravila Zevalin in podpornem zdravljenju, ki lahko vključuje tudi rastne faktorje.
The risk of developing secondary myelodysplasia or leukaemia following therapy with alkylating agents is well known. 
Tveganje za pojav sekundarne mielodisplazije ali levkemije po zdravljenju z alkilirajočimi zdravili je dobro znano.
In]-radiolabelled Zevalin, blood sampling, and the MIRDOSE3 software program. 
In] označenim zdravilom Zevalin, iz vzorcev krvi in s programsko opremo MIRDOSE3.
• Secondary malignancies 
• Sekundarne maligne bolezni
Do not use Zevalin after the expiry date which is stated on the pack. 
Zdravila Zevalin ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini.
Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. 
Izpostavljanje ionizirajočemu sevanju je povezano z nastankom raka in možnostjo razvoja genetskih okvar.
Control of these metals can be achieved either through process validation or release test. 
Te kovine se kontrolirajo bodisi z validacijo postopka ali s testiranjem ob sproščanju.
In patients experiencing a severe mucocutaneous reaction treatment must be discontinued. 
Pri bolnikih s hudimi mukokutanimi reakcijami se mora zdravljenje prekiniti.
Store the vials in the original container in order to protect from light. 
Viale shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
Close monitoring for evidence of extravasation during the injection of Zevalin is required in order to avoid radiation-associated tissue damage. 
Potrebno je skrbno spremljanje pojava ekstravazacije v času injiciranja zdravila Zevalin, da se prepreči poškodovanje tkiva zaradi sevanja.
Y]-radiolabelled Zevalin must only be received, handled and administered by qualified personnel and must be prepared in accordance with both radiation safety and pharmaceutical quality requirements (for more details see also sections 4.4, 6.6 and 12). 
Y] označeno zdravilo Zevalin sme sprejeti, uporabljati in aplicirati le strokovno usposobljeno osebje, ki ga mora pripraviti v skladu z zahtevami za varstvo pred sevanjem in farmacevtsko kakovost (za več podrobnosti glejte tudi poglavja 4.4, 6.6 in 12).
The benefit of Zevalin following rituximab in combination with chemotherapy has not been established. 
Korist uporabe zdravila Zevalin po zdravljenju z rituksimabom v kombinaciji s kemoterapijo, ni bila potrjena.
The path length of beta emission (90) by yttrium-90 in tissue is 5 mm. 
Domet delcev (sevanja) beta (90) itrija-90 v tkivu je 5 mm.
The product of radioactive decay is stable zirconium-90. 
Produkt radioaktivnega razpada je stabilen cirkonij-90.
Y] ibritumomab tiuxetan in a total volume of 10 ml. 
Y] ibritumomab tiuksetana v skupnem volumnu 10 ml.
If your doctor plans to treat you with some other antibody after treatment with Zevalin, you will need to be tested for special antibodies. 
Če vas namerava vaš zdravnik zdraviti z drugimi protitelesi po zdravljenju z zdravilom Zevalin, boste morali opraviti tudi preiskave za določena protitelesa.
Their receipt, storage, use, transfer and disposal are subject to the regulations and/or approporiate licences of the competent official organisation. 
Za njihov sprejem, shranjevanje, uporabo, prenos in odstranjevanje veljajo predpisi in/ali ustrezna dovoljenja/licence pristojne uradne organizacije.
Total organic carbon (e.g. organic chelators) 
Skupni organski ogljik (npr. organski kelatorji)
PFS increased from 13.5 months (control) to 37 months (Zevalin; p<0.0001; HR 0.465). 
PFS se je podaljšalo s 13,5 mesecev (kontrolne osebe) na 37 mesecev (Zevalin, p < 0,0001, razmerje ogroženosti 0,465).
Complete Response Rate (%) 
Popolni odgovor (%)
The Zevalin therapeutic regimen was administered in two steps (see 4.2). 
Terapija z zdravilom Zevalin je potekala v dveh fazah (glejte poglavje 4.2).
• severe mucous membrane reactions, which may occur days or months after Zevalin and/or rituximab administration. 
• hude reakcije sluznice, ki se lahko pojavijo dneve ali mesece po dajanju zdravila Zevalin in/ali riuksimaba.
Empty 
prazna
10 ml of formulation buffer 
10 ml pufra za pripravo formulacije
Infusions must be administered under the close supervision of an experienced physician with full resuscitation facilities immediately available (for radiopharmaceutical precautions see also sections ‘4.2 and 12'). 
Infuzijo se daje pod skrbnim nadzorom izkušenega zdravnika v prostoru, ki je ustrezno opremljen s celotno, takoj dosegljivo opremo za oživljanje (za previdnostne ukrepe v zvezi z radiofarmaki glejte tudi poglavji 4.2 in 12).
• Risk Management Plan (RMP) The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in version 1.1 of the Risk Management Plan (RMP) presented in Module 1.8.2 of the Marketing Authorisation Application and any agreed subsequent updates of the RMP. 
Imetnik dovoljenja za promet z zdravilom bo izvedel študije in dodatne farmakovigilančne aktivnosti, podrobno opisane v farmakovigilančnem načrtu, dogovorjenem v različici 1.1 načrta za obvladovanje tveganja (RMP), predloženi v modulu 1.8.2 vloge za dovoljenje za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
Appropriate aseptic precautions must be taken, complying with the requirements of Good Manufacturing Practice of pharmaceuticals. 
Upoštevati je treba ustrezne previdnostne ukrepe za zagotavljanje aseptičnih pogojev, ki so v skladu z Dobro proizvodno prakso za zdravila.
Due to the exposure to ionising radiation derived from the radiolabel, a risk of mutagenic and carcinogenic effects has to be taken into account. 
Zaradi izpostavljenosti ionizirajočemu sevanju, ki izvira iz radioaktivnega markerja, je treba upoštevati možnost mutagenih in tumorogenih učinkov.
Grade 3 and grade 4 infections were reported commonly. 
Pogosto so poročali o okužbah 3. in 4. stopnje.
In clinical studies, the [ 
V kliničnih študijah je povzročilo z [
After radiolabelling, immediate use is recommended. 
Po označevanju z radioizotopom se priporoča takojšnja uporaba.
In case of a potential severe infusion reaction treatment must be stopped immediately. 
V primeru potencialno hude reakcije je treba zdravljenje z infuzijo takoj prekiniti.
These reports originated either from clinical trials or from postmarking experience. 
Poročila izvirajo iz kliničnih preskušanj ali iz obdobja trženja.
In particular, your doctor will need to interrupt treatment with growth factors such as filgrastim for a period of three weeks before giving you Zevalin to two weeks after Zevalin treatment. 
Vaš zdravnik bo moral prekiniti predvsem zdravljenje z rastnimi faktorji kot je filgrastim za obdobje treh tednov, v katerem prejemate zdravilo Zevalin, in dva tedna po zdravljenju z zdravilom Zevalin.
Zevalin is not recommended for use in children and adolescents below 18 years due to a lack of data on safety and efficacy. 
Uporaba zdravila Zevalin se ne priporoča pri otrocih in mladostnikih, mlajših od 18 let, ker ni na voljo dovolj podatkov o varnosti in učinkovitosti.
The safety and efficacy of immunization with any vaccine, particularly live viral vaccines, following therapy with Zevalin have not been studied. 
Študij varnosti in učinkovitosti imunizacije s katerimkoli cepivom, zlasti z živimi virusnimi vakcinami, po zdravljenju z zdravilom Zevalin niso izvedli.
Since Zevalin is used after pretreatment with rituximab (for details see section 4.2), see also the prescribing information of rituximab. 
Ker se zdravilo Zevalin uporablja po predhodnem zdravljenju z rituksimabom (za podrobnosti glejte poglavje 4.2), glejte tudi informacije o predpisovanju rituksimaba.